IP Library Granted Patent US 7,846,674
Granted Patent B2
US 7,846,674 · App. 11/472,069 · Granted Dec 7, 2010

Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6

Assignee: Roche Diagnostics Operations, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,674
App. No.
11/472,069
Granted
Dec 7, 2010
Kind
B2
Abstract

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Claims (8)

1. An in vitro method for specific and sensitive diagnosis of rheumatoid arthritis in a patient, the method comprising

measuring in a sample from the patient a concentration of anti-cyclic citrullinated peptide (anti-CCP) autoantibody and a concentration of interleukin 6,

mathematically combining the concentrations into a single combined value,

comparing the combined value to a multivariate cut-off level for a marker panel consisting of anti-CCP autoantibody and interleukin 6 determined in a reference population to be determinative of rheumatoid arthritis, and

diagnosing rheumatoid arthritis where the combined value is greater than the multivariate cut-off level.

2. The method of claim 1 wherein the measuring step further includes measuring in the sample a concentration of serum amyloid A (SAA) and wherein the marker panel consists of anti-CCP antibody, interleukin 6, and SAA.

3. A kit for performing the method of claim 1 comprising reagents required to measure the concentrations of anti-CCP and interleukin 6 in said sample.

4. A kit for performing the method of claim 2 comprising reagents required to measure the concentrations of anti-CCP, interleukin 6, and SAA in said sample.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: WILD, NORBERT; GRUNERT, VEIT PETER; KARL, JOHANN; ZOLG, WERNER
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 019222/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 019222/0518 →
Priority Claims (1)
EP 03029658 · Dec 23, 2003 · regional
Continuity (2)
Continuation PCTEP200401452700 · Dec 21, 2004
Related Publication 20070264673A1 · Nov 15, 2007